At MDRNA we are focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics against human diseases including critical unmet medical needs in areas such as oncology, inflammation and metabolic disorders.

13 November 2008: MDRNA, Inc. Announces Third Quarter 2008 Financial Results

06 November 2008: MDRNA, Inc. to Hold Third Quarter 2008 Earnings Conference Call on Thursday, November 13, 2008, at 4:30 p.m. Eastern Time